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Abstract
The African swine fever virus A238L protein inhibits calcineurin phosphatase activity and activation of NF-κB and p300 co-activator. An 82
amino acid domain containing residues 157 to 238 at the C-terminus of A238L was expressed in E. coli and purified. This purified A238L
fragment acted as a potent inhibitor of calcineurin phosphatase in vitro with an IC50 of approximately 70 nM. Two putative nuclear localisation
signals were identified between residues 80 to 86 (NLS-1) and between residues 203 to 207 overlapping with the N-terminus of the calcineurin
docking motif (NLS-2). Mutation of these motifs independently did not reduce nuclear localisation compared to the wild type A238L protein,
whereas mutation of both motifs significantly reduced nuclear localisation of A238L. Mutation of the calcineurin docking motif resulted in a
dramatic increase in the nuclear localisation of A238L provided an intact NLS was present. We propose that binding of calcineurin to A238L
masks NLS-2 contributing to the cytoplasmic retention of A238L.
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African swine fever virus (ASFV) is a large, cytoplasmic
DNA virus and is the only member of the Asfarviridae family.
The virus encodes between 156 and 167 ORFs, many of which
are not essential for virus replication in cells but have important
roles in virus/host interactions. These include a number
encoding proteins which inhibit host defence pathways (Dixon
et al., 2005). One of these, the A238L protein, has been reported
to inhibit signalling pathways in infected cells by three diffe-
rent mechanisms; inhibition of NF-κB activation, inhibition of
the activity of calcineurin (CaN) phosphatase (now known as
protein phosphatase 3C or PP3C) resulting in inhibition of
pathways dependent on CaN including activation of NFAT
transcription factor (Hogan et al., 2003) and inhibition of the
transcriptional co-activator p300 (Granja et al., 2004, 2006b;
Miskin et al., 1998; Powell et al., 1996; Revilla et al., 1998).⁎ Corresponding author. Institute for Animal Health Pirbright Laboratory, Ash
Road, Pirbright, Surrey GU24 0NF, UK. Fax: +44 1483 232448.
E-mail address: linda.dixon@bbsrc.ac.uk (L.K. Dixon).
0042-6822/$ - see front matter. Crown Copyright © 2008 Published by Elsevier In
doi:10.1016/j.virol.2008.01.005A238L is predicted to act as a potent immunosuppressive pro-
tein by inhibiting transcriptional activation of the broad range of
immunomodulatory genes dependent on these pathways. So
far reports have shown that A238L is involved in inhibiting
transcription from the TNF-α, cycloxygenase-2 and inducible
nitric oxide synthase genes which results in reduced production
of inflammatory mediators NO, prostaglandins and TNF-α from
infected cells (Granja et al., 2006a, 2004, 2006b; Miskin et al.,
1998; Powell et al., 1996; Revilla et al., 1998). The A238L
gene is conserved in all ASFV isolates analysed. Deletion of the
A238L gene from the genome of a virulent isolate did not reduce
virus virulence in pigs (Neilan et al., 1997), possibly other genes
may compensate for the loss of A238L. The A238L protein is
238 amino acids long and contains a central region encoding 4
ankyrin-like repeats, an N-terminal domain of unknown func-
tion and a C-terminal domain which contains a docking motif
involved in binding to CaN (Miskin et al., 2000; Neilan et al.,
1997; Revilla et al., 1998). The ankyrin repeats in the A238L
protein resemble those in the IκBα inhibitor of NF-κB acti-
vation. In resting cells NF-κB is present in a complex with IκB
inhibitor proteins (Wietek and O’Neill, 2007). Activation by ac. All rights reserved.
Fig. 1. Inhibition of CaN phosphatase activity by the A238L157–238 fragment.
Panel a) shows proteins purified from E. coli strain BL21 which were
transformed with either pET32a vector alone or pET32a containing A238L
fragment encoding residues 157 to 238. Protein expression was induced by
addition of IPTG and the His-tagged proteins were purified from extracts
by nickel affinity chromatography. Purified proteins were separated by SDS-
PAGE and blotted onto PVDF membranes. The His-tagged proteins were
detected using ant-His antibodies followed by HRP-conjugated Protein A.
Bound antibodies were detected by enhanced chemiluminescence. Lane 1 shows
the Trx protein tag purified from bacteria transformed with pET32a vector and
lane 2 shows the Trx-A238L157–238 fusion protein purified from bacteria
transformed with the vector containing the A238L insert. The position of
molecular weight markers run in parallel is indicated. In Panel b) the effect
of varying concentrations of these proteins on CaN phosphatase activity is
shown. The concentration (nM) of either the Trx-A238L157–238 fusion protein
or the Trx protein alone added to each reaction is indicated on the X-axis.
The CaN phosphatase activity measured in cpm of [32P] released from a
phosphorylated substrate peptide is indicated on the y-axis. Data from a re-
presentative experiment is shown and represents means from 3 replicates.
Standard deviation error bars are shown.
478 C.C. Abrams et al. / Virology 374 (2008) 477–486variety of stimuli leads to phosphorylation dependent ubiquiti-
nylation of IκB and degradation by the proteasome. Nuclear
localisation signals on NF-κB are exposed resulting in its trans-
location into the nucleus and activation of genes containing the
NF-κB binding sites in the promoter. The similarity between the
ankyrin repeats in A238L and those in IκB suggested that A238L
may act as a homologue of IκB to inhibit the stimulus induced
activation of NF-κB that occurs following virus infection. This
was supported by experiments which demonstrated that expres-
sion of A238L inhibits transcriptional activation of an NF-κB
dependent luciferase reporter gene (Powell et al., 1996; Revilla
et al., 1998). The A238L protein was shown, by co-precipitation,
to be present in a complex with the p65 subunit of NF-κB,
although, direct interaction between A238L and the p65 subunit
of NF-κB has not been demonstrated (Revilla et al., 1998; Tait
et al., 2000). In one study A238L was shown to be predominantly
localised in the cytoplasm at 8 h post-infection (Tait et al., 2000).
However, our data showed that the A238L protein is present in
both the cytoplasm and nucleus of cells and accumulates in the
nucleus at later times post-infection (from 10 to 18 hpi). A238L
was shown to be actively imported into the nucleus and exported
by a CRM-1 dependent pathway (Silk et al., 2007). Two forms of
the A238L protein are expressed during infection, a 28 kDa and
32 kDa form. These are thought to differ by post-translational
modification, although the nature of themodification has not been
defined (Tait et al., 2000). The higher molecular weight form
accumulates in the nucleus and is preferentially co-precipitated
with the p65 subunit of NF-κB (Tait et al., 2000). Expression of
A238L does not inhibit nuclear accumulation of NF-κB p50
or p65 subunits. Recombinant A238L added to nuclear extracts
inhibits binding of NF-κB to its binding elements in gene
promoters in electromobility shift assays and displaced prebound
NF-κB from DNA (Revilla et al., 1998). These data provide
support for a model whereby A238L acts in the nucleus to inhi-
bit NF-κB activation.
Evidence that A238L acts by modulating the function of the
transcriptional co-activator CREB binding protein/p300 comes
from studies using cell lines expressing A238L. In a Jurkat
T cell line A238L inhibited expression from the TNF-α pro-
moter by modulating NF-κB, NFAT and c-Jun transactivation
by a mechanism that involves CREB binding protein/p300
function (Granja et al., 2006a). A238L inhibition of transcrip-
tion from the cyclooxygenase-2 promoter depended on NFAT
elements within the promoter and was reversed by a cons-
titutively active CaN. This suggested that inhibition of CaN was
involved in this process. However, the data showed that binding
of NFAT to DNA was not inhibited, but that transactivation of
p300 by a GAL4/NFAT fusion protein was inhibited (Granja
et al., 2004). LPS and IFN-γ stimulated transcription of the
inducible nitric oxide synthase (iNOS) gene promoter was
inhibited in the RAW 264.7 mouse macrophage cell line ex-
pressing A238L. In this study A238L was shown to inhibit p65
and p300 interaction and inhibited p65/rel A and p300 bind-
ing to distal NF-κB sequence in the iNOS promoter. In these
experiments A238L also abrogated p300 transactivation me-
diated by a GAL4 p300 fusion protein. These results also
suggest that A238L acts within the nucleus possibly by inter-fering with the activation of the transcriptional co-activator
CREB binding protein/p300 (Granja et al., 2006b). The mode of
A238L action may depend on the stimulus delivered, cell and
promoter type.
Fig. 2. Domains and mutant forms of A238L used in studies of its subcellular localisation. Panel a) schematically illustrates the structure of A238L illustrating the
position of the ankyrin repeats (Ank1 to 4), predicted NLS (NLS-1 and -2), CaN binding domain (CaN bd) and CaN inhibitory domains. Panel b) shows the sequence
of the CaN inhibitory domain including residues 157 to 238 from the A238L protein of the BA71V strain and the Malawi LIL20/1 strain. Panel c) shows the sequence
of the NLS-1, NLS-2 and CaN binding domain from the wild type A238L and mutant forms used in these studies. The ability of the expressed proteins to bind to CaN
as determined previously is indicated by ‘Yes’ or ‘No’.
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which A238L functions. In particular little is known about func-
tional domains within the A238L protein. A peptide containing the
motifwhich is essential for binding ofA238L toCaNdid not inhibit
phosphatase activity, suggesting that additional sequences from
A238L are required for this inhibition (Miskin et al., 2000). Here
we demonstrate that the C-terminal 82 amino acid domain of
A238L effectively inhibits CaN phosphatase activity. Previously
we showed that the A238L protein is actively imported into the
nucleus and exported by a CRM-1 dependent pathway. Here we
evaluate the role of two putative nuclear localisation signals (NLS)
in the nuclear translocation of A238L. Our results show that mu-
tation of either NLS alone does not alter the nuclear accumulation
of A238L but that mutation of both significantly reduces nuclear
import. In addition we show that mutating the CaN docking motif
of A238L results in increased accumulation into the nucleus
providing an intact NLS is present. Thus binding of A238L to CaN
may result in increased retention of A238L in the cytoplasm.
Results
A238L calcineurin phosphatase inhibitory domain
Our previous data identified critical residues that are required for
binding to CaN, PxIxITxC/S within the sequence PKIIITGC atresidues 206 to 213 close to the C-terminus of A238L. A 14 amino
acid peptide containing residues 200 to 213, which included these
residues, bound with high affinity to CaN but did not inhibit its
phosphatase activity (Miskin et al., 2000). This suggested that other
residues from A238L or possibly another protein, are required to
inhibit CaN. In order to identify this domain, we cloned the 3′ end
of the A238L gene encoding the C-terminal 82 amino acids from
residues 157 to 238 in the bacterial expression vector pET32a. The
A238L sequenceswere fused downstream from the 100 amino acid
Trx tag from the thioredoxin gene. Polyhistidine tags were also
present in frame with the A238L fragment. The plasmid was
transformed into E. coli strain BL21 and, following induction of
expression, a protein of molecular weight 27 kDa was detected in
extracts from bacteria transformed with the plasmid expressing
157–238-A238L-polyhistidine. This protein was not detected in
extracts from bacteria transformed with the vector plasmid alone,
instead an additional protein of 17 kDa was detected following
induction of expression. These proteins were detected by western
blotting using an antibody which binds to the polyhistidine tag,
confirming that they were the proteins expressed from the pET32a
vector (see Fig. 1a). The 157–238-A238L-Trx fusion protein and
the Trx tag expressed from the vector alone were purified byNickel
affinity chromatography and the amount of protein quantified.
Varying concentrations of this purified A238L-polyhistidine fusion
protein, ranging between 60 nM to 720 nM, were added to in vitro
Fig. 3. Effect of mutating NLS-2 and the CaN binding domain on the subcellular distribution of A238L. Vero cells were transfected with plasmids expressing
different versions of PK-taggedA238L under the control of theA238L promoter and infectedwithASFVBA71VVIKGal strain. After incubation for 13 h cells were treated
with or without LMB (40 nM) 3 h prior to fixation. Permeabilised cells were incubated with antibodies against the PK-tag to detect the A238L proteins, followed by Alexa
Fluor 488 conjugated goat anti-mouse IgG secondary antibody and imaged using confocal microscopy. Panel a) shows representative images of the subcellular localisation
of PK-tagged A238L. This was characterised as either, preferentially nuclear (N), both nuclear and cytoplasmic (N/C) or preferentially cytoplasmic (C). Panel b) shows
images from control experiments inwhich a plasmid expressing IκB fused to the PK-tagwas transfected into cells and thesewere either treated or untreatedwith LMB.Panel
c) shows the percentage of cells exhibiting predominantly nuclear (N), predominantly cytoplasmic (C), or nuclear and cytoplasmic (N/C) distributions for each A238L
constructed and tested and under each condition. Data represents 3 independent experiments for which 100 cells were counted for each treatment. Means and standard
deviation error bars are shown. The properties of each plasmid tested are shown beneath the graph. A cross (+) represents a functional CaN binding site, NLS-1 and NLS-2
and a bar (−) represents non-functional motifs.
480 C.C. Abrams et al. / Virology 374 (2008) 477–486calcineurin phosphatase assays. The ability of these fragments to
inhibit the release of [32 P] from a phosphorylated substrate of CaN
was measured in reactions containing 100 nM concentration of
CaN (Fig. 1b). This showed that the 157–238-A238L-polyhistidine
protein inhibited CaN in a dose dependent manner varying from
45% inhibition at 60 nM concentration to 80% at 150 nM andmore
than 90% at 720 nM. The IC50 was estimated to be 70 nM. In
contrast, no inhibition was observed when comparable amounts of
control Trx tag protein purified from bacteria transformed with the
pET32a vector without insert was added to the CaN phosphatase
assays. A similar percentage inhibition was observed when either
the CaN autoinhibitory peptide or cyclosporine A, cyclophilin
complexes were added to reactions (data not shown). These results
show that theC-terminal domain ofA238L containing residues 157and 238 alone is a very effective inhibitor of CaN phosphatase and
that no additional proteins are required. The estimated IC50 is
comparable to that reported for other inhibitors of CaN including
carabin, cyclosporine A/cyclophilin complexes and calcipressin.
Attempts were made to further define the domain of A238L re-
quired to inhibit CaN phosphatase by subcloning a fragment con-
taining residues 157 to 213 and testing in in vitro assays using the
same strategy. The results showed this fragment did not inhibit CaN
even at concentrations up to 600 nM (data not shown). A peptide
was synthesised which contained residues 191 to 220 fromA238L.
Thiswas tested for its ability to inhibit CaNphosphatase activity but
no inhibition was observed even at concentrations up to 600 nM
(data not shown). Although no inhibition of CaN activity was
observed with these fragments of A238L, we cannot exclude the
481C.C. Abrams et al. / Virology 374 (2008) 477–486possibility that this was because the fragments did not fold in their
native format.
Sequences involved in the nuclear localisation of A238L
Previous data had suggested that A238L is present both in
the cytoplasm and in the nucleus and that a proportion of the
protein is actively transported into the nucleus and exported by
a CRM-1 dependent pathway (Silk et al., 2007). In order to
define signals in A238L that may be involved in nuclear
localisation and to determine if interaction with CaN may af-
fect the localisation of A238L, we observed the subcellular
localisation of a series of mutants of the A238L protein by
confocal microscopy. Analysis of the A238L protein sequence
using the PSORT programme (Horton et al., 2006), which
predicts putative nuclear localisation signals (NLS), identified
two (see Fig. 2). These NLSs consist of short stretches of amino
acids, highly enriched in basic residues. One of these (NLS-1)
is located close to the N-terminus of A238L near the C-terminus
of the first ankyrin repeat domain and includes amino acids 80
to 86 (PHRRDKD). The second (NLS-2), which includes the
sequence KKKPK between amino acids 202 to 206, is loca-
ted close to the C-terminus adjacent to and overlapping the
PxIxITxC/S CaN binding domain. Mapping the NLS-1 motif
onto the model of the predicted structure of A238L, suggests
it is on the surface of the A238L protein. The NLS-2 sequence
is also predicted to be located on the surface since it overlaps the
CaN binding site.
To determine if the predicted signals NLS-1 and NLS-2
are involved in the nuclear localisation of A238L, mutations
were generated in each of these sites separately and in both sites
(Fig. 2). The subcellular localisation of the expressed A238L
proteins was examined by confocal microscopy by using anti-
bodies against the PK-epitope tag fused at the N-terminus of
the gene. Plasmids expressing A238L under the control of the
A238L promoter and containing mutations within the CaN
binding motif have been described previously (Miskin et al.,
2000). Plasmids W13-A238L and B19-A238L contain muta-
tions within the predicted NLS-2. Although plasmidW20-A238L
contains a P to S mutation, this is not predicted to disrupt NLS-2.
The proteins W20-A238L and W13-A238L do not bind to
CaN whereas the WT-A238L and B19-A238L proteins bind
CaN (Fig. 2) (Miskin et al., 2000).
An additional plasmid was constructed which had muta-
tions within the predicted NLS-1. This plasmid (pcDNA3-
A238L 84–88) encodes 5 G residues at amino acid positions 84–
88, instead of the wild type sequence, DKDGN. This was
predicted by the PSORT programme to inactivate the NLS-1
sequence present between residues 80–86. This mutant form of
the A238L protein was cloned under control of its own promoter
and fused to the PK-epitope tag (pFlanks-WT-NLS-1). A 310 bp
N-terminal fragment of A238L containing these mutations in
NLS-1, was inserted into the plasmids described above which
contain mutations within the predicted NLS-2 and CaN bind-
ing domain. The amino acid sequence of the regions including
NLS-1 and NLS-2 and the CaN binding properties of all of these
plasmids are described in Fig. 2.The effect of disrupting NLS-2 was first examined by trans-
fection of plasmids expressing wild type and mutant A238L
proteins under control of their own promoter into ASFV-infected
Vero cells. The subcellular distribution of A238L was examined
at late times post-infection by confocal microscopy in both the
presence and absence of leptomycin B (LMB) to inhibit CRM-1
mediated nuclear export (Fig. 3a and b). All of these plasmids
encode an intact NLS-1. Plasmids pFlanks-W13-A238L and
B19-A238L contain mutations which are predicted to disrupt
NLS-2; W13-A238L encodes a protein which does not bind
CaN and B19-A238L binds to CaN. As mentioned above, the
P to S mutation in plasmidW20-A238L does not disrupt NLS-2,
but the expressed protein does not bind to CaN. The distribution
of A238L was scored as predominantly nuclear, predominantly
cytoplasmic or distributed between the nucleus and cytoplasm.
Three independent experiments were performed and distribu-
tions were scored in 100 cells for each treatment (see Fig. 3.).
Both W13-A238L and B19-A238L showed a similar sub-
cellular distribution to wild type A238L in both the absence
and presence of LMB (Fig. 3c). This showed that disruption of
the NLS-2 motif alone was not sufficient to alter or prevent the
nuclear accumulation of A238L. Surprisingly, in cells trans-
fected with the plasmid expressing W20-A238L, which has an
intact NLS-2 but disrupted CaN binding motif, a dramatic
increase in the number of cells exhibiting a predominantly
nuclear distribution was observed compared to the wild type
protein, both in untreated cells and cells treated with LMB. This
observation was particularly dramatic in cells treated with LMB
since the proportion of cells showing a nuclear distribution of
A238L increased from approximately 25% for wild type A238L
to greater than 70% for W20-A238L. The number of cells
showing a predominantly nuclear distribution was also sig-
nificantly increased in the absence of LMB: from approximately
2% for wild type A238L to approximately 30% forW20-A238L.
Since disruption of the CaN binding site significantly increases
the nuclear accumulation of A238L a likely hypothesis is that the
interaction between wild type A238L and CaN masks NLS-2,
contributing to the retention of a proportion of A238L in the
cytoplasm of ASFV-infected cells. The difference observed
between untreated cells and those treated with LMB confirm our
previous results (Silk et al., 2007) and indicate that a proportion
of A238L is exported from the nucleus by a CRM-1 mediated
pathway.
The effect of mutating NLS-1 alone, and in combination
with NLS-2, was also examined. The subcellular localisation of
A238L in the presence and absence of LMB was examined
following transfection of 4 plasmids expressing forms of A238L
which all had mutations in NLS-1 (A238L-NLS-1, W13-
A238L-NLS-1, W20-A238L-NLS-1 and B19-A238L-NLS-1).
A238L-NLS-1 does not contain mutations in NLS-2 and, al-
though W20-A238L-NLS-1 has a mutation of the P to S residue
(see Fig. 2), this is not predicted to interfere with the function of
NLS-2. WT-A238L-NLS-1 and B19-A238L-NLS-1 bind CaN
whereas W20-A238L-NLS-1 and W13-A238L-NLS-1 do not
bind CaN. W13-A238L-NLS-1 and B19-A238L-NLS-1 both
contain a disrupted NLS-2; W13-A238L-NLS-1 does not bind
CaN whereas B19-A238L-NLS-1 does bind CaN. As shown
Fig. 4. Effect of mutating NLS-1, NLS-2 and the CaN binding domain on the subcellular distribution of A238L. Vero cells were transfected with plasmids expressing
different versions of PK-tagged A238L under the control of its promoter and infected with ASFV BA71V vIKGal strain. After incubation for 13 h cells were treated
with or without LMB (40 nM) 3 h prior to fixation. Permeabilised cells were incubated with antibodies against the PK-tag to detect the A238L proteins, followed by
Alexa Fluor 488 conjugated secondary antibody. A238L was detected by indirect immunofluorescence. Cells were imaged using confocal microscopy. The percent of
cells exhibiting predominantly nuclear (N), predominantly cytoplasmic (C), or nuclear and cytoplasmic (N/C) distributions was determined for each A238L
constructed and tested and under each condition. Data represents 3 independent experiments for which 100 cells were counted for each treatment. Means and standard
deviation error bars are shown. The properties of each plasmid tested are shown beneath the graph. A cross (+) represents a functional CaN binding site, NLS-1 and
NLS-2 and a bar (−) represents non-functional motifs.
482 C.C. Abrams et al. / Virology 374 (2008) 477–486(Fig. 4), the expressed WT-A238L-NLS-1 protein showed a
similar subcellular distribution to wild type A238L, indicating
that disruption of NLS-1 alone was not sufficient to alter the
nuclear accumulation of A238L. The protein expressed from
plasmidW20-A238L-NLS-1 showed a similar distribution to that
expressed from the parental W20 plasmid, (see Figs. 3c and 4)
and, as discussed above, a significant increase was detected in the
nuclear accumulation of these A238L proteins compared to WT
A238L. This supports our hypothesis that disruption of the CaN
binding domain results in increased nuclear accumulation of
A238L, provided that a functional NLS is present.
In contrast to these results, when cells were transfected
with plasmids expressingW13-A238L-NLS-1 and B19-A238L-
NLS-1, which contain mutations within both NLS-1 and NLS-2,
a dramatic decrease in the number of cells exhibiting a pre-
dominately nuclear distribution was observed. In the presence
of LMB, less than 15% of the cells examined showed a pre-
dominately nuclear distribution for both W13-NLS-1-A238L and
B19-NLS-1-A238L, compared to greater than 50% for WT-
A238L. In the absence of LMB a significantly higher proportion of
cells transfectedwithW13-A238L-NLS-1 andB19-A238L-NLS-1
exhibited a predominantly cytoplasmic distribution (approxi-
mately 50%) compared to those transfected with a plasmid
expressing WT-A238L (b10%). Therefore mutation of both
NLS-1 and NLS-2 together significantly reduced the nuclear
accumulation of A238L, although nuclear translocation of
A238L was not completely abolished. This suggests that, in
addition to NLS-1 and NLS-2, another mechanism may operate
to facilitate the nuclear localisation of A238L. Taken toge-
ther these results indicate that both of these NLS play a sig-
nificant role in the nuclear localisation of A238L, and appear toact independently with one compensating for the loss of the
other.
Mutation of residues within the A238L ankyrin repeats does not
alter the ability to inhibit NF-κB dependent gene expression
The mechanism by which A238L inhibits NF-κB activity has
not been defined. Although A238L has been shown to be co-
precipitated from cells with the p65 subunit of NF-κB (Revilla
et al., 1998; Tait et al., 2000), direct interaction of these proteins
has not been demonstrated. However, the presence of ankyrin
repeats in A238L suggests that these may make direct contact
with NF-κB, as has been reported for IκB. Determination of the
structure of IκB in complex with NF-κB (Huxford et al., 1998)
showed that non-contacting amino acids play a role in the
formation of this complex. The most important of these residues
are found within 20 Å of residues Asn 202 and Ser 203 of the
P65 subunit of NF-κB (Huxford et al., 1998). The structure of
the central domain of A238L containing the ankyrin repeats was
modelled using the DeepView software and the structure of
IκBα as substrate. Comparison of this model of A238L with
that of IκBα identified those residues on A238L which were
predicted to be within a 20 Å radius of the 202 and 203 residues
of p65 and potentially to make contact with p65. These included
two groups of residues between 84 to 88 and 121 to 125 which
were highly conserved in the A238L sequences from all ASFV
isolates. These residues are located within the ankyrin repeats
and are predicted to be solvent exposed on the loop structures.
To determine if mutation of these residues altered the ability
of A238L to inhibit NF-κB dependent gene transcription, three
mutant forms of A238L were tested. The residues 84 to 88
Fig. 5. Effect of mutations in A238L protein on inhibition of NF-κB activation.
Sequences encoding residues 84–88 and 121–125 of A238L were mutated as
shown in panel a). Plasmids expressing A238L proteins containing these
mutations were co-transfected into LPK15a cells with a plasmid expressing the
luciferase reporter gene under control of an NF-κB dependent element. Cells
were stimulated with PMA, LPS and ionomycin and after 4 h extracts were
prepared and tested for luciferase activity. The plasmid transfected is indicated
on the x-axis. The y-axis indicates luciferase activity as a percentage of that
observed in stimulated cells transfected with vector alone and also shows the
percentage inhibition of this activity. Results from a typical experiment
including triplicate samples are shown in panel b). Mean and standard deviation
error bars are shown.
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residues to Gs was described above (A238L-NLS-1). Two ad-
ditional mutant forms of A238L were constructed. One of these
had mutated sequences encoding residues 121 to 125 to either
G or S (A238L 121_125). The third mutant (A238L 84+121)
combined both sets of mutations in residues 84 to 88 and 121 to
125. To test the effect of these mutant forms of A238L on
activation of NF-κB dependent transcription, the plasmids ex-
pressing mutant forms or wild type A238L were co-transfected
into PK15a cells with an NF-κB dependent luciferase reporter
construct. Cells were stimulated with PMA, LPS and ionomycin
to activate NF-κB and the level of activation assayed by mea-
suring luciferase activity in cell extracts. The expression of
wild type A238L inhibited the activation of NF-κB depen-
dent gene transcription by 78% compared to stimulated cells
(Fig. 5) whereas expression of A238L-NLS-1 inhibited NF-κB
activation by 68% and expression of A238L 121_125 inhibited
NF-κB activation by 69%. Expression of the A238L mutant,
A238L 84+121, which combined both of these mutations, also
inhibited NF-κB activation by 69%. Therefore mutation of these
groups of residues both individually and combined had a com-
paratively small effect on the ability of A238L to inhibit NF-κB
activation.Discussion
A238L is the only protein known to combine the functions of
inhibiting both CaN phosphatase activity and activation of NF-κB.
The importance of these pathways as targets for immunosup-
pressive drugs means that there is considerable interest in defi-
ning the molecular mechanisms by which these dual functions
of A238L are mediated and the functional consequences. Pre-
viously a CaNdockingmotif of sequence PKIIITGCwas identified
in the C-terminal domain of A238L. This domain contains critical
residues PxIxITxC/S required for binding of A238L to CaN. A 14
amino acid peptide, including this motif and adjacent residues,
bound to CaNwith high affinity (Kd 600 nM) but did not inhibit its
phosphatase activity, suggesting that additional residues were
required for inhibition. These might be either from A238L or
another protein which might associate with A238L (Miskin et al.,
2000a). Here we show that an 82 amino acid C-terminal domain of
A238L very effectively inhibits CaN phosphatase activity at low
concentrations (IC50 is approximately 70 nM) indicating that this
fragment binds to CaN with high affinity to inhibit its phosphatase
activity.
The CaN docking motif in A238L closely resembles those in
substrate proteins of CaN including NFAT 1–4 (Aramburu et al.,
1998, 1999) and the yeast transcription factor Crz1 (Roy et al.,
2007) as well as cellular inhibitors of CaN including members
of the calcipressin family and cabin/cain (Aubareda et al., 2006;
Liu, 2003; Martinez-Martinez and Redondo, 2004; Sun et al.,
1998).
Although all of these proteins share the conserved residues
PxIxIT in their CaN docking sequence, other residues both in the
core motif and surrounding residues differ considerably. There is
strong evidence supporting a model whereby the sequence of
these other residues in the docking motif determines the affinity
of binding to CaN. A random screening approach identified
the peptide containing core residues PVIVIT which bound to
CaN with higher affinity than the docking peptide identified in
NFAT (PRIEIT) (Aramburu et al., 1998, 1999). Replacement of
the CaN docking motif in the CaN substrates NFAT and the
yeast Crz1 protein with the PVIVIT sequence resulted in their
constitutive dephosphorylation and activation (Aramburu et al.,
1998; Roy et al., 2007). In the NFAT protein a second site
involved in binding to CaN has been identified and it is propo-
sed that this is a lower affinity interaction which is brought
into contact with CaN following initial binding to the PRIEIT
sequence. This brings the hyperphosphorylated residues on
NFAT in contact with the active site following displacement of
the autoinhibitory peptide of CaN (Garcia-Cozar et al., 1998;
Park et al., 2000). The structure of the PVIVIT peptide in
complex with CaN has recently been solved by NMR. These
results showed that the PVIVIT peptide binds as a β-strand on
the edge of aβ-sheet of CaN. The side chains of the core residues
PxIxIT make extensive interactions with conserved residues in
CaN. Non-conserved residues are solvent exposed and sequence
variations can modulate the Kd of the interaction (between 1 μM
to 1 mM) (Li et al., 2007; Takeuchi et al., 2007). We showed
previously that a 14 amino acid residue peptide containing the
docking motif from A238L competed more strongly for binding
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supporting the hypothesis that A238L may bind to CaN via this
docking motif with higher affinity than NFAT (Miskin et al.,
2000). We propose that this interaction brings additional resi-
dues from A238L into contact with CaN, resulting in inhibition
of phosphatase activity, possibly by blocking access to the active
site. Other possibilities such as conformational changes in CaN
induced by the binding cannot be excluded. Our demonstration
that a purified recombinant protein containing the C-terminal 82
amino acids of A238L inhibits CaN phosphatase activity very
effectively with an IC50 comparable to other defined CaN in-
hibitors (IC50 in the nM range) shows that no other proteins are
required for the inhibition. We have not further defined the
sequences in A238L required for inhibiting CaN. There is no
obvious sequence similarity with the second site in NFAT (Cn B)
that is required for binding to CaN or with inhibitory domains
from the defined CaN endogenous inhibitors (Hogan et al.,
2003). Sequence comparison of A238L proteins from 9 different
isolates show that these share between 75 and 100% identity
(Neilan et al., 1997) and residues in the C-terminal domain are
very well conserved.
Previous data has shown that A238L is present in both the
cytoplasm and nucleus of cells and that a proportion is active-
ly imported into the nucleus and exported by a CRM-1 mediated
pathway (Silk et al., 2007). Here we have examined the role of
two predicted NLS signals, one located within the first anky-
rin repeat and the other immediately adjacent to the CaN docking
motif. We showed that mutation of each of these independently
did not significantly alter the nuclear accumulation of A238L
when compared to the wild type A238L. However, when both
of these putative NLS were mutated, nuclear accumulation
of A238L was significantly reduced compared to mutation of
either NLS alone or the wild type A238L. This suggests that
both of these putative NLS are involved in nuclear import of
A238L and that one can compensate for loss of the other.
Mutation of the CaN docking motif, which is adjacent to and
partially overlaps with the NLS-2, resulted in a dramatic increase
in nuclear accumulation of A238L when the NLS-2 signal was
intact. In contrast expression of mutant A238L, with both a
disrupted CaN docking motif and NLS-2 signal did not result
in any increased nuclear accumulation compared to wild type
A238L. An attractive hypothesis is that binding of CaN to
A238L masks this NLS-2 and this contributes to retention of
A238L in the cytoplasm. In this case theNLS-1, which is close to
the N-terminus of A238L and distant from the CaN binding
domain, may be exposed and direct nuclear translocation of
A238L. We observed increased nuclear accumulation of the
higher molecular weight form of A238L at late times post-
infection compared to early times (Silk et al., 2007). This form of
A238L was shown to be preferentially co-precipitated with the
p65 subunit of NF-κB suggesting it may function primarily to
inhibit NF-κB activity. Possibly post-translational modification
of A238L may disrupt its binding to CaN exposing NLS-2 and
enhancing the nuclear localisation of this modified form of
A238L. Binding of CaN to the lower molecular weight form
of A238L may enhance cytoplasmic retention of this form of
the protein.The detailed mechanism by which A238L inhibits NF-κB
activation remains unclear. AlthoughA238L can be co-precipitated
with the p65 subunit of NF-κB, direct interaction between the
proteins has not been demonstrated. Herewe havemutated residues
of A238L predicted to be important for interaction with p65 and
shown that there was no dramatic effect of these mutations on the
ability of A238L to inhibit NF-κB activation.
No other proteins have been described which have the dual
functions of inhibiting both CaN and NF-κB pathways. However
endogenous inhibitors of CaN combined with other pathways
have been described. One such endogenous inhibitor is the
ubiquitously expressed Cabin 1/cain CaN protein. This consists
of more than 2200 amino acids and contains functional domains
in addition to the CaN inhibitory domain. A region containing
multiple ligands for SH3 domains is required for binding of Cabin
1/cain to amphiphysin, a component of a protein complex res-
ponsible for calcium dependent synaptic vesicle release. A model
was proposed in which Cabin 1/cain serves as a negative regula-
tor of CaN and neurotransmitter endocytosis. In addition to its
function as a negative regulator of CaN, Cabin 1/cain was shown
to act as a transcriptional repressor of the myocyte enhancing
factor (MEF)-2 family of transcription factors. This may provide a
mechanism to integrate regulation of both CaN dependent and
MEF2 pathways. An endogenous inhibitor of CaN, named
Carabin, has recently been identified, which also inhibits the Ras
signalling pathway through its intrinsic Ras GTPase-activating
protein (GAP) activity. Expression of this inhibitor is induced
through the T cell signalling pathway. As a negative feedback
inhibitor of the CaN signalling pathway that also mediates cross-
talk between CaN and Ras, Carabin may provide a mechanism
for feedback regulation of pathways including T cell activation
(Pan et al., 2007). Evidence suggests that the main role of the
A238L protein is to inhibit the activation of host defence path-
ways dependent on CaN and NF-κB which occurs in response to
virus infection. Targeting of these pathways by A238L em-
phasises their importance in regulating the host's defences in
infected macrophages.
CaN and NF-κB pathways are important targets for im-
munosuppressive drugs. Understanding how A238L inhibits
both pathways will provide new leads for drug discovery. Here
we have identified a short domain of 82 amino acids which acts
as a potent inhibitor of CaN.
Materials and methods
Viruses and cells
The Vero cell-adapted ASFV strain BA71V with the A238L
gene deleted, vIKGAL, has been described previously (Miskin
et al., 1998). Vero cells were used for infections with ASFV.
Vero cells and PK15a (Gilpin et al., 2003) cells were used for
transfections.
Construction of plasmids
The fragments of A238L encoding residues 157 to 238 and
157 to 213 from the Malawi LIL 20/1 isolate were amplified by
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the 5′ and 3′ ends respectively. These fragments were digested
with Bam HI and Hind III and cloned into the pET32a vector
(Novagen), which had been digested with the same enzymes.
Sequences encoding residues 84 to 88 and 121 to 125 of
A238L were mutated using the Stratagene quick change sys-
tem. The respective fragments were amplified by PCR from
plasmid pcDNA3-A238L (Miskin et al., 1998) using oligonu-
cleotides CTCATAGGAGGGGTGGAGGTGGAGGCTCTGC
TTTACATTATTTAG and CTAAATAATGTAAAGCA-
GAGCCTCCACCTCCACCCCTCCTATGAG or GGGAC-
CAAAATTTGTTTACCGGGTTCTGGTGGGGG -
GACTCCTGTG and CACAGGAGTCCCCCCACCAGAACC
CGGTAAACAAATTTTGGTCCC. These oligonucleotides
introduce the following mutations, residues 84 to 88 change
from DKDGN to GGGGG and residues 121–125 are changed
from NFNGM to GSGGG, respectively.
The plasmids pFlanks-A238L, pFlanks-W13-A238L, pFlanks-
W20-A238L, and pFlanks-B19-A238L have been described
previously (Miskin et al., 2000). These contain upstream promoter
sequences of the A238L gene and either the wild type A238L gene
from Malawi LIL 20/1 isolate or forms of the gene containing
mutations in the CaN docking motif as described previously
(Miskin et al., 2000). The PK-tag is fused at the N-terminus of the
A238L gene in all plasmids. The plasmids pFlanks-WT-A238L-
NLS-1, pFlanks-W13-A238L-NLS-1, pFlanks-W20-A238L-
NLS-1, and pFlanks-B19-A238L-NLS-1 were constructed by in-
serting a fragment containing the mutated version of the predicted
NLS-1 site into plasmids pFlanks-A238L, pFlanks-W13-A238L,
pFlanks-W20-A238L, and pFlanks-B19-A238L. This was ac-
hieved by PCR amplification of a fragment encoding amino acids 1
to 103 from the pcDNA3-A238L84–88 plasmid using forward and
reverse primers containing an Xho1 site and EcoN1 site res-
pectively. The resulting PCR product was digested with Xho1 and
EcoN1 and ligated into the appropriate backbone plasmid from
which the same fragment had been removed by digestion. The
sequence of all plasmids was confirmed. The NF-κB dependent
luciferase reporter plasmid was a gift from Prof. Ron Hay, Uni-
versity of Dundee and was used previously to measure the effect
of A238L.
Expression and purification of proteins from E. coli
The pET32a vector containing fragments from A238L and
the vector without insert, were transformed into E. coli strain
BL21 and cultures incubated at 37 °C. Expression of the proteins
was induced by addition of IPTG and 2 h after induction bacteria
were pelleted and lysed by suspension in buffer containing
50 mM Tris pH 8.0, 1 mM DTT, 10 mM imidazole, 300 mM
NaCl, 0.1% NP40 and a mixture of protease inhibitors (Sigma),
followed by sonication for 5 bursts of 30 s. The expressed
proteins were purified using His Trap columns (GEHealthcare)
according to the manufacturer's instructions. Purified proteins
were stored at −80 °C in aliquots. The amount of protein present
was determined using the Protein Assay Kit (Biorad) and by
comparison with a known amount of protein markers run on
SDS-PAGE and detected by silver staining. Proteins sampleswere separated by SDS-PAGE and either detected by silver
staining or blotted onto Hybond C membranes (GE Health care)
and detected with anti-His antibody (GE Healthcare) followed
by secondary antibodies. Bound antibodies were detected by
enhanced chemiluminescence.
CaN phosphatase assays
Purified CaN (100 nM Sigma) and calmodulin (600 nm
Sigma) were incubated for 30 min. with 32P-labelled RII phos-
phopeptide in 60 μl reactions containing 12 mM Tris–HCl
(pH 7.5), 3.5 mMMgCl2, 17 mM CaCl2, 8 mM 2-mercaptoetha-
nol, and 58 μg/ml bovine serum albumin. CaN phosphatase
activity was measured by release of [32P]-phosphate from the RII
phosphopeptide (Fruman et al., 1996). Where indicated recombi-
nant proteins were added to the reactions.
Infection and transfection
Vero cells or PK15a cells were seeded into 35 mm wells of a
6 well plate at a density of 1×106 and incubated at 37 °C, 5%
CO2, for 24 h. Vero cells were infected with ASFV for 2 h then
transfected with 5 μg of plasmid DNA using lipofectin or
lipofectamine according to the manufacturer's recommenda-
tions (Invitrogen). After transfection for 5 h at 37 °C, 5% CO2,
the transfection reagent was replaced with 3 ml of antibiotic free
DMEM and incubated for further periods as indicated.
SDS-PAGE gel electrophoresis and Western blotting
Protein samples were prepared in SDS-PAGE sample load-
ing buffer and heated at 90 °C for 5 min to denature the pro-
tein sample. Proteins were resolved at 100 V on 12.5% Tricine
SDS-PAGE gels. Where appropriate a small aliquot of the pro-
tein sample was removed for quantification prior to the ad-
dition of loading buffer. Gels were either silver stained or
transferred to PVDF membrane, 0.2 μm, for Western blot ana-
lysis. Western blots were probed with anti-His antibody (GE
Healthcare) at a dilution of 1/1000 followed by HRP-conjuga-
ted Protein A. Bound antibodies were detected by enhanced
chemiluminescence.
Confocal microscopy
Cell monolayers were grown on 22×22 mm glass cover slips
in 35 mm wells and fixed for 20 min in PBSe containing 4%
paraformaldehyde. The cells were permeabilised in 1% Triton
X-100 in PBSe for 15 min then incubated in 0.5% BSA in PBSe
for 30 min to inhibit non-specific antibody binding. They were
incubated with primary antibody diluted in 0.5% BSA/PBSe for
1 h and after washing in secondary antibody diluted in 0.5%
BSA/PBSe for 1 h. After washing cells were mounted onto glass
slides using VectaShield mounting medium with Dapi (Vector
Laboratories). The cells were visualised using Leica TCS SP2
confocal microscopy. The primary antibody used was mouse
anti-PK-tag (Serotec) 20 μg/ml and the secondary antibody was
Alexa Fluor 488 goat anti-mouse 10 μg/ml.
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PK15a cells were transfected with either a NF-κB luciferase
expression plasmid or both the NF-κB luciferase expression plas-
mid and an A238L expression plasmid, as previously described.
After incubation for 18 h post-transfection cells were stimulated by
the addition of 100 nM Phorbol 12-myristate 13-acetate (PMA),
10 μg/ml Lipopolysacharide (LPS) and 4 nM Ionomycin for 4 h to
induce NF-κB activity. The cells were then harvested using the
Promega (USA) Luciferase assay system according to the manu-
facturer's instructions. Sample measurement was performed using
a BioOrbit 1253 luminometer (Turku, Finland) according to the
instructions provided by Promega.
Protein modelling
The structure of A238L was modelled using the DeepView
software package (Guex and Peitsch, 1997). Themodel of A238L
is based upon the atomic coordinates from the crystal structure of
IκB, as these two proteins share significant homology within the
region of the ankyrin repeats. As the significant homology only
encompasses the central region of A238L, the model lacks the
first 52 amino acids from the N-terminus and last 55 amino acids
from the C-terminus.
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